Tamoxifen improves 20-year distant recurrence-free interval for Luminal A and B breast cancerTamoxifen reduces long-term breast cancer recurrence in specific subtypes

This study is a secondary analysis of a randomized controlled trial involving 952 patients with estrogen receptor-positive and HER2-negative tumors, specifically categorized as luminal A and luminal B subtypes. The study was conducted at the Regional Cancer Center Stockholm-Gotland in Sweden. The primary objective was to evaluate the long-term impact of tamoxifen on distant recurrence-free intervals over a 20-year follow-up period.

The intervention group received at least 2 years of tamoxifen therapy, while the comparator group received no endocrine therapy. This design allowed researchers to assess the durability of treatment effects in patients with these specific tumor characteristics over two decades.

Regarding primary outcomes, the data revealed significant improvements for both subtypes. For Luminal A tumors, the 5-year distant recurrence-free interval was 93% in the tamoxifen group compared to 89% in the control group (a 4% absolute difference). At the 20-year mark, the 20-year distant recurrence-free interval for Luminal A patients was 76% with tamoxifen versus 66% without it, representing a 10% absolute difference. Multivariable analysis for Luminal A showed an adjusted hazard ratio (HR) of 0.57 (95% CI = 0.42 to 0.78).

For Luminal B tumors, the results showed even larger absolute improvements. The 5-year distant recurrence-free interval was 72% for those treated with tamoxifen compared to 57% in the control group (a 15% absolute difference). At the 20-year follow-up, the 20-year distant recurrence-free interval for Luminal B patients was 55% with tamoxifen versus 37% without it, an 18% absolute difference. Multivariable analysis for Luminal B yielded an adjusted hazard ratio (HR) of 0.68 (95% CI = 0.46 to 0.99).

Safety and tolerability data were not reported in this secondary analysis. Consequently, specific adverse event rates, serious adverse events, or treatment discontinuation rates are unknown from this dataset. While the randomized trial design supports a causal link between tamoxifen and reduced risk of distant recurrence, the lack of safety data means clinical decisions regarding side effects cannot be drawn from this specific paper.

Methodologically, this study is limited by being a secondary analysis of older trial data collected between 1976 and 1997. While the long-term follow-up provides valuable insights into the durability of tamoxifen's effect, the historical nature of the data may not reflect modern clinical practices or contemporary supportive care. Clinically, these results indicate that tamoxifen provides a significant reduction in the risk of distant recurrence for both Luminal A and Luminal B tumors. The magnitude of benefit is notably higher in the Luminal B subtype at the 20-year mark. These findings support the continued use of tamoxifen as an effective long-term endocrine therapy for these patients. However, questions remain regarding how modern supportive care might impact outcomes compared to this historical cohort and whether newer endocrine therapies offer superior profiles for specific subtypes.